FLI Colloquium with Stefan Hüttelmaier: Targeting RNA binding proteins (RBPs) and microRNAs in cancer therapy


On November 23, Prof Stefan Hüttelmeier, cell biologist at the Institute of Molecular Medicine at the Martin Luther University Halle-Wittenberg, will present preclinical evidence for the use of oncoRBPs and oncomiRs in cancer therapy in his lecture at the FLI.

Oncofetal RNA binding proteins (oncoRBPs) like the IGF2 mRNA binding proteins (IGF2BPs) are essential modulators of mRNA fate in embryogenesis, stem cells and cancer progression. In concert with microRNAs, in particular oncomiRs like miR-21-5p, oncoRBPs promote essentially all hallmarks of cancer. Recent progress in the development of RBP-centered small molecules, impairing RNA-association of oncoRBPs, and circular RNAs serving as oncomiR decoys, emphasize prospects of targeting the disturbed cytoplasmic control of gene expression in cancer therapy. Preclinical evidence for the target potential and feasibility of implementing oncoRBPs and oncomiRs in cancer care will be presented.


Title of Talk:Targeting RNA binding proteins (RBPs) and microRNAs in cancer therapy
When:Thursday, November 23, 2023, 3:00 pm
Where:Seminar room “Nucleus”, main building (FLI 1), Beutenbergstraße 11, Jena
Host:       Helen Morrison (Group leader Nerve regeneration)

The colloquium will be a hybrid event. Details for accessing the session will be provided before the colloquium takes place. For external guests: Please contact Ivonne.Roeppnack-Jahnke@~@leibniz-fli.de for details.